Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infectious complications · people undergoing gastrointestinal surgery
It is very uncertain whether preoperative enteral nutrition (standard formula) changes infectious complications compared with usual care or control (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in non‐ infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
2 findings from 1 review
Pain (POSAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Quality of life · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Adherence · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found